Geographic variations in the PARADIGM-HF heart failure trial

Geographic variations in the PARADIGM-HF heart failure trial

AIMS The globalization of clinical trials has highlighted geographic variations in patient characteristics, event rates, and treatment effects. We investigated these further in PARADIGM-HF, the largest and most globally representative trial in heart failure (HF) to date. METHODS AND RESULTS We looked at five regions: North America (NA) 602 (8%), Western Europe (WE) 1680 (20%), Central/Eastern...

Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?

DOI: 10.5935/abc.20160009 In the first semester of this year, the U.S. Food and Drug Administration (FDA) approved a new drug for the treatment of heart failure, LCZ696, commercially known as Entresto. This new treatment option was evaluated by the FDA on a priority basis (fast track designation), which allowed a faster release than usual. In Brazil, the drug is being evaluated by the National ...

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

Heart failure (HF) is a global health problem with an estimated prevalence of over 5.8 million in the USA and over 23 million worldwide. It represents the most common cause of hospitalization in elderly patients (≥ 65 years) and its incidence has a growing trend mainly due to the aging of the population. Neurohumoral activation plays a major role in the pathophysiology. So in consequence, the c...

PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?

PARADIGM-HF After several years of a disappointing series of negative clinical trials investigating novel therapies for systolic heart failure, the presentation of the landmark PARADIGM-HF [Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure] trial at the 2014 Congress of the European Society of Cardiology in Barcelona, with simultaneo...

The need to apply the best therapy in heart failure – the era after PARADIGM-HF